-
November 26, 2020 01:35 PM IST Her suggestion could possibly lessen the burden on the government, which is grappling to get a measure of the exact cost to vaccinate the entire country and getting the logistics and supply chain in place to administer the vaccine. It is estimated that it could cost a minimum of Rs 50,000 crore to vaccinate the country.
-
October 27, 2018 08:01 AM IST “We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.
- February 12, 2018 09:37 PM IST
The government is calling it the "world's largest government healthcare scheme"--- the showpiece announcement of the Budget 2018 was a healthcare assurance scheme.
- January 25, 2018 05:06 PM IST
We are going to expand our biosimilars pipeline both with Mylan and Sandoz and beyond on our own, said Kiran Mazumdar Shaw, CMD, Biocon.
- January 24, 2018 02:35 PM IST
EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.
- January 19, 2018 12:32 PM IST
The company is trying to combine forces with companies who have been successful in biosimilars, said Kiran Mazumdar Shaw, CMD, Biocon.
- December 08, 2017 03:37 PM IST
Ajanta Pharma retains the tag of fastest wealth creator for the third time in a row and Asian Paints is the most consistent wealth creator, said the wealth creation study
- December 04, 2017 04:49 PM IST
In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said Trastuzumab approval is a huge milestone. It has been under development for seven years.
- December 01, 2017 09:50 AM IST
European Medicines Agency (EMA) has accepted the Trastuzumab application for review. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon spoke at length about the same.
- October 27, 2017 04:25 PM IST
In an interview to CNBC-TV18, Kiran Mazumdar Shaw, Chairperson & MD of Biocon spoke about the results and her outlook for the company.
- October 10, 2017 11:04 AM IST
In an interview to CNBC-TV18, Vishal Manchanda, Pharma Analyst at Nirmal Bang Institutional Equities shared his views and readings on the news as well as on Biocon stock.
- October 09, 2017 02:38 PM IST
Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.
- September 08, 2017 01:49 PM IST
Small booster for Biocon as they have received a certificate of good manufacturing practices (GMP) compliance from the European regulator for its insulin manufacturing facility in Malaysia.
- August 16, 2017 05:49 PM IST
“The request for withdrawal of the dossiers and re-submission is part of EMA procedural requirements linked to this re-inspection and will be considered by the EMA’s Committee for Medicinal Products of Human Use (CHMP),” the company said.
- July 10, 2017 02:42 PM IST
There appears to be a setback for Biocon as its biosimilars program hits a roadblock in Europe -- the drug products unit inspection done in March has not received the GMP certificate by the French regulator. In an interview to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon spoke about the latest happenings in the company.
- June 11, 2017 06:38 PM IST
Watch the interview of Kiran Mazumdar-Shaw, CMD of Biocon, Rakesh Biyani, Joint MD at Future Retail, Gnanesh Gala of Navneet Education, Harsh Mariwala of Marico, Bharat Madan, Group CFO at Escorts and KU Subbiah, CFO, VST Tillers Tractors in which they shared their views on how goods and services tax (GST) will impact businesses across the country.
- April 29, 2017 03:58 PM IST
Biocon chairperson Kiran Mazumdar-Shaw told Moneycontrol that the company is focusing on ramping up its biologics business, which accounts for 15 percent of overall revenues, but has the potential to be a game changer.
- March 03, 2017 11:11 PM IST
Biocon Chief Kiran Mazumdar Shaw says India is not an outsourced services country anymore, it is an innovation and knowledge partner.
- March 02, 2017 05:19 PM IST
Biotech company, Biocon will see two crucial inspections later this month and in early April. Company‘s manufacturing sites will come up for inspections by the European medicines agency later this month and next will be an inspection by the US FDA.
- February 17, 2017 10:33 AM IST
Biocon Thursday announced the US Food and Drug Administration has accepted Mylan‘s Biologics License Application (BLA) for biosimilar chemotherapy drug Pegfilgrastim for review. Sharing details on the development with CNBC-TV18 Biocon Chairperson and Managing Director Kiran Mazumdar Shaw said, "This is a very important acceptance."
- January 25, 2017 05:25 PM IST
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
- January 12, 2017 12:48 PM IST
Following US president-elect Donald Trump‘s explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.
- December 22, 2016 12:31 PM IST
Biocon is among the companies that gave a good performance in 2016 and the stock surged 80 percent this year. Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of the company, said the company has gained traction in many emerging markets with its biosimilars.
- December 06, 2016 02:31 PM IST
Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said huge opportunities exist for Biocon in the US biosimilars market.
- November 10, 2016 08:27 AM IST
In an interview with CNCB-TV18, Kiran Mazumdar Shaw, CMD of Biocon said that people worldwide are losing confidence in entrenched political systems and many feel marginalized and neglected from the economic developments that happen.
